Stockscreener 앱 받기
1.97
0.51%
0.01
시간 외 거래:
2.00
0.03
+1.52%
Alx Oncology Holdings Inc 주식(ALXO)의 최신 뉴스
ALX Oncology (ALXO) Holds Near $1.96 as Biotech Stock Consolidates Below ResistanceSingle Stock ETF - dars.gov.et
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A - Stock Titan
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ALX Oncology Holdings Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
ALX Oncology (NASDAQ:ALXO) Issues Earnings Results - MarketBeat
ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary - TradingView
ALXO: Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028 - TradingView
Is ALX Oncology Holdings Inc (ALXO) Turning a Corner After Q2 Ea - GuruFocus
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
ALX Oncology Reports Q2 2026 Net Loss of $18 Million - Quiver Quantitative
ALX Oncology reports Q2 2026 net loss of $18.0M, $153.4M cash; advances evorpacept and ALX2004 - TradingView
ALXO: Reduced net loss, robust cash position, and advancing clinical milestones drive outlook - TradingView
Clinical pipeline accelerates as ALX Oncology posts Q2 results and updates on ALX2004 study - tradersunion.com
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating - Moomoo
ALXO Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ALX Oncology (ALXO) Projected to Post Earnings on Tuesday - MarketBeat
ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key LevelsUnusual Call Volume - dars.gov.et
ALX Oncology Holdings Inc (ALXO) Institutional Confidence - TradingKey
ALXO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Redmile Group LLC Acquires 4,699,470 Shares of ALX Oncology Holdings Inc. $ALXO - MarketBeat
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC - MarketBeat
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
ALX Oncology Holdings Inc (ALXO) Cash Flow - TradingKey
2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC - MarketBeat
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010 - TradingKey
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.020|Chg%:-0.010 - TradingKey
TradingKey - TradingKey
ALX Oncology Holdings Inc. Revenue Breakdown – NASDAQ:ALXO - TradingView
ALX Oncology Holdings Inc (ALXO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alx Oncology Holdings, Inc. (ALXO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alx Oncology Holdings, Inc. (ALXO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alx Oncology Holdings, Inc. (ALXO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
ALX Oncology (ALXO) Status Update Summary - Quartr
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology Holdings (ALXO) Posts Modest Gain as Stock Holds Above Key SupportHidden Order - dars.gov.et
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
ALXO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ALX Oncology (ALXO) Jefferies London Healthcare Conference 2025 Summary - Quartr
ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations - Stock Titan
ALXOAlx Oncology Holdings Inc Options - Finviz
ALX Oncology (ALXO) Edges Higher as Biotech Sector Shows Selective InterestLast Point Support - DonanımHaber
ALX Oncology Appoints New Chairman Amid Leadership Changes - The Globe and Mail
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology grants 500,000-share option to new general counsel - Stock Titan
ALX Oncology's Corey Goodman resigns as Chairman and director - TradingView
Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair - Stock Titan
ALX Oncology names Scott Garland chairman, adds general counsel - Investing.com UK
ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com - Investing.com India
ALXO Welcomes New Leadership with Board Changes - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - Investing News Network
ALX Oncology appoints Scott Garland as chairman and Michael Listgarten as general counsel to strengthen leadership - Traders Union
ALX Oncology (ALXO) Slides 5.91% as Selling Pressure Persists Near Key SupportBollinger Walk - dars.gov.et
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2500 Growth Benchmark - marketscreener.com
1.80%
1.77%
자본화:
|
볼륨(24시간):